Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56801
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tipattaraporn Panich | en_US |
dc.contributor.author | Khajornsak Tragoolpua | en_US |
dc.contributor.author | Supansa Pata | en_US |
dc.contributor.author | Chatchai Tayapiwatana | en_US |
dc.contributor.author | Nutjeera Intasai | en_US |
dc.date.accessioned | 2018-09-05T03:30:25Z | - |
dc.date.available | 2018-09-05T03:30:25Z | - |
dc.date.issued | 2017-02-01 | en_US |
dc.identifier.issn | 15578852 | en_US |
dc.identifier.issn | 10849785 | en_US |
dc.identifier.other | 2-s2.0-85012237115 | en_US |
dc.identifier.other | 10.1089/cbr.2016.2126 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85012237115&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/56801 | - |
dc.description.abstract | © Mary Ann Liebert, Inc. 2017. Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN) accelerates tumor invasion and metastasis via activation of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA) expression. The authors were interested in whether the scFv-M6-1B9 intrabody against EMMPRIN that retains EMMPRIN in endoplasmic reticulum could be a potential tool to suppress cervical cancer invasion through inhibition of uPA. The chimeric adenoviral vector Ad5/F35-scFv-M6-1B9 was transferred into human cervical carcinoma HeLa cells to produce the scFv-M6-1B9 intrabody against EMMPRIN. Cell surface expression of EMMPRIN, the membrane-bound uPA, the enzymatic activity of secreted uPA, and the invasion ability were analyzed. The scFv-M6-1B9 intrabody successfully diminished the cell surface expression of EMMPRIN and the membrane-bound uPA on HeLa cells. uPA activity from tissue culture media of EMMPRIN-downregulated HeLa cells was decreased. The invasion ability of HeLa cells harboring scFv-M6-1B9 intrabody was also suppressed. These results suggested that the scFv-M6-1B9 intrabody might represent a potential approach for invasive cervical cancer treatment. The application of scFv-M6-1B9 intrabody in animal experiments and preclinical studies would be investigated further. | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Medicine | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | Downregulation of extracellular matrix metalloproteinase inducer by scFv-M6-1B9 intrabody suppresses cervical cancer invasion through inhibition of urokinase-type plasminogen activator | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | Cancer Biotherapy and Radiopharmaceuticals | en_US |
article.volume | 32 | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.